NRXP vs. SNSE, ITRM, UBX, ACST, LPCN, BFRG, FBRX, BIOR, LUMO, and APRE
Should you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Sensei Biotherapeutics (SNSE), Iterum Therapeutics (ITRM), Unity Biotechnology (UBX), Acasti Pharma (ACST), Lipocine (LPCN), Bullfrog AI (BFRG), Forte Biosciences (FBRX), Biora Therapeutics (BIOR), Lumos Pharma (LUMO), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical preparations" industry.
Sensei Biotherapeutics (NASDAQ:SNSE) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.
In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 7 mentions for NRx Pharmaceuticals and 5 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.61 beat NRx Pharmaceuticals' score of -0.21 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.
Sensei Biotherapeutics received 15 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 75.86% of users gave Sensei Biotherapeutics an outperform vote.
Sensei Biotherapeutics currently has a consensus price target of $4.00, indicating a potential upside of 164.90%. Given NRx Pharmaceuticals' higher possible upside, equities analysts plainly believe Sensei Biotherapeutics is more favorable than NRx Pharmaceuticals.
Sensei Biotherapeutics' return on equity of 0.00% beat NRx Pharmaceuticals' return on equity.
Sensei Biotherapeutics has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 25.5% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 21.1% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Sensei Biotherapeutics and NRx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get NRx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NRx Pharmaceuticals Competitors List
Related Companies and Tools
